Objectives
The Research Development Program aims to support CRISM QA node members in the development of research projects and protocols that seek to:
improve the practices (prevention or treatment) for groups and people affected by problematic use of opioids and other substances
contribute to the field’s knowledge with new evidence
Why is the CRISM QA offering a research development program (RDP) to its members?
Foster collaborations within the node, nationally, and internationally
- Build research capacity and competitive projects
- Provide a space and mechanism for regional priorities identification
- Support members to develop competitive research protocols or improve existing protocols
- Address the increasing challenges of accessing granting competition (more applicants, fewer funds)
Although this funding opportunity/competition attracts CRISM QA Node members with experience in the competitive research grant application environment, we strongly encourage node members with less experience to seek collaboration opportunities with CRISM Quebec Atlantic Researchers to submit eligible protocols and projects to the RDP for review.
Categories of Admissible Research Activities
Applicants are invited to submit a concept sheet proposal to obtain financial support in order to:
- Generate preliminary data or structuring activities (for example, intersectoral consultations, collection, or organization of data) related to the development of a new research protocol;
- Develop a new research protocol for submission to a recognized granting agency;
- Improve a research protocol that has already been submitted, well assessed but has not received the funding requested in the competition.
A maximum of $10,000 can be awarded to an emerging project proposal (category 1 or 2). A maximum of $15,000 can be awarded to a promising project proposal (category 3). The number of awards will depend on funds available.
Supported projects
Sex Differences and Menstrual Phase Fluctuations in Cannabis-Related Psychiatric Emergency Department Presentations
Dr. Amanda Hudson (Dalhousie University, NS)
Developing an Innu First Nations evaluation framework for implementing a community-wide FASD prevention strategy in two communities
Dr. Melody E. Morton Ninomiya (Wilfrid Laurier University, NFL/ON)
Drinking to cope with interpersonal conflict as a pathway to problem drinking in women: Does romantic relationship conflict matter most?
Dr. Sherry Stewart (Dalhousie University, NS)
Exploring cannabis harm reduction strategies for women through community-based participatory research
Dr. Stephen Ellenbogen (Memorial University of Newfoundland, NFL)
Exploration of Therapies for Opioid Use Problems in a First Nation in Nova Scotia
Dr. Dennis Wendt, Department of Educational and Counselling Psychology (McGill University)
Treatment of Depression in Individuals with Opiod Use Disorder: A Randomized Placebo-Controlled Trial
Dr Didier Jutras-Aswad (Université de Montréal, Qc)
Substance Use Cessation Therapies for those At-Risk in Early Intervention Services for Psychosis: Research Protocol Development
Dr Phil Tibbo (Dalhousie University, NS)
Opioid Use following Opiod Prescription for Non-Specific Low Back Pain in Nova Scotian Emergency Departments
Dr Jill Hayden (Dalhousie University, NS)
Suivi de la cohorte bas seuil en traitement de la dépendance aux opioïdes RELAIS du programme CRAN
Marie-Ève Goyer (University of Montreal, QC)
Evaluating the effectiveness of prescription monitoring programs to reduce inappropriate opioid prescribing and related-harms: A feasibility study
Mark Asbridge (Dalhousie University, NS)
Mon buzz
Mathieu Goyette and Dr. Jorge Flores-Aranda (University of Sherbrooke, QC)
Scaling up access to personality-targeted interventions for youth at risk of substance use disorders in the United States and Canada: A hybrid effectiveness-implementation facilitation trial.
Patricia Conrod (University of Montreal QC) and Dr. Sherry Stewart (Dalhousie University, NS)
A Phase II randomized, double-blind, placebo-controlled multicenter study of Desvenlafaxine for depression in patient with opioid dependence (DESV TRIAL)
Dr. Didier Jutras-Aswad (University of Montreal, QC)
